Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2703196 | 0.89 | PTGS1 (0.48) | SLC6A4SLC6A3MAPTPDGFRBKDR | |
| SCHEMBL19835339 | 0.87 | MALT1 (0.49) | SLC6A4SLC6A3MAPTPDGFRBKDR | |
| SCHEMBL28642445 | 0.86 | CTSA (0.55) | SLC6A4SLC6A3MAPTPDGFRBKDR | |
| SCHEMBL30791358 | 0.86 | CTSA (0.55) | SLC6A4SLC6A3MAPTPDGFRBKDR | |
| SCHEMBL2490439 | 0.85 | PDGFRB (0.53) | MAPTPDGFRBKDRMAPK1L3MBTL1 | |
| SCHEMBL442533 | 0.81 | MAP4K4 (0.55) | MAPTCNR1 | |
| SCHEMBL5359287 | 0.81 | CNR1 (0.62) | CNR1 | |
| SCHEMBL28414233 | 0.81 | MALT1 (0.57) | MAP2K4GABRA5CSNK2A2CSNK2BKDM4E | |
| SCHEMBL2703081 | 0.80 | CNR1 (0.65) | SLC6A4SLC6A3TACR2CNR1ABL1 | |
| SCHEMBL27335814 | 0.80 | RPS6KB1 (0.49) | MAPTPDGFRBKDRGABRA5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| EP-2066636-B1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | disclosed |
| US-7812028-B2 | 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7781593-B2 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101522626-A | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | CN | disclosed |
| CN-101516849-A | 5-phenyl-nicotinamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | CN | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| EP-2066636-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | HOFFMANN-LA ROCHE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008031734-A1 | 5-PHENYL-NICOTINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | SLC6A4 3498/4885SLC6A3 3023/4885MAPT 4139/4885 |
| US-20080070931-A1 | CB1 cannabinoid receptor antagonists/inverse agonists; 5-(4-chloro-phenyl)-N-((1R,2R)-2-hydroxy-cyclohexyl)-6-(3-methoxy-propyl)-nicotinamide for example; eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, drug abuse | CNR2, CNR1, GPR119 | SLC6A4 651/4885SLC6A3 634/4885MAPT 3075/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | SLC6A4 3498/4885SLC6A3 3023/4885MAPT 4139/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | SLC6A4 3498/4885SLC6A3 3023/4885MAPT 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.